新辅助化疗对乳腺癌ER,PR,Her-2,Ki-67表达的影响

Effect of neoadjuvant chemotherapy on expression of ER,PR,Her-2 and Ki-67 in breast cancer

目的探讨新辅助化疗(NAC)对于乳腺癌ER(雌激素受体)、PR(孕激素受体)、Her-2(人表皮生长因子受体-2)、Ki-67(细胞增殖指数)表达的影响。方法收集乳腺癌患者CE-T(环磷酰胺+表柔比星+多西他赛)方案新辅助化疗前后ER,PR,Her-2,Ki-67变化情况的临床资料,统计分析新辅助化疗对其影响。结果 40例乳腺癌患者新辅助化疗前后ER,PR,Her-2变化无统计学差异(P均>0.05);而Ki-67指数在经过新辅助化疗后表达明显降低(P<0.05)。47例患者中经过新辅助化疗后达到病理完全缓解7例,病理完全缓解率为14.89%,其中ER,PR表达弱者更易达到(P<0.05),而Her-2对疗效并无显著影响(P>0.05)。结论新辅助化疗对ER,PR,Her-2的影响无统计学意义,但可明显降低Ki-67表达,且ER,PR表达越低的乳腺癌患者对新辅助化疗的敏感性越高,越容易达到病理完全缓解。

Objective To investigate the effect of NAC on the expression of ER（ estrogen receptor）,PR（ progesterone receptor）,Her-2（ human epidermal growth factor receptor-2）,Ki-67（ nuclcar-associated antigen Ki-67） in breast cancer. Methods The clinical data of ER,PR,Her-2,Ki-67 of breast cancer patients before and after CE-T（ cyclophosphamide epirubicin） neo-adjuvant chemotherapy were collected and the influence of NAC on it was analysed. Results There was no statistical difference between 40 breast cancer patients before and after NAC（ P〈0. 05）; The expression of Ki-67 index decreased after NAC（ P〈0. 05）. And in the 47 patients,7 cases were reached pathologic complete response,and the rate was 14. 89%. ER and PR were more vulnerable to pathological CR by our analysis（ P〈0. 05）,but Her-2 had no significant effect on the curative effect（ P〉0. 05）. Conclusion No significant effect of NAC on ER,PR,Her-2,but the expression of Ki-67 is significantly decreased. And the lower the ER and PR expression,the higher the sensitivity of the breast cancer patient,the more easily to achieve complete pathological remission.